These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 29484893)

  • 21. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.
    Pugliese D; Guidi L; Ferraro PM; Marzo M; Felice C; Celleno L; Landi R; Andrisani G; Pizzolante F; De Vitis I; Papa A; Rapaccini GL; Armuzzi A
    Aliment Pharmacol Ther; 2015 Oct; 42(7):880-8. PubMed ID: 26235565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-Tumor Necrosis Factor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients.
    Andrade P; Lopes S; Gaspar R; Nunes A; Magina S; Macedo G
    Dig Dis Sci; 2018 Mar; 63(3):746-754. PubMed ID: 29349693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?
    Denadai R; Teixeira FV; Saad-Hossne R
    Arq Gastroenterol; 2012; 49(2):172-6. PubMed ID: 22767007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor Necrosis Factor Inhibitor-Induced Psoriasis in a Pediatric Crohn's Disease Patient Successfully Treated with Ustekinumab.
    Bonomo L; de Moll EH; Li L; Geller L; Gordon MI; Dunkin D
    J Drugs Dermatol; 2020 Mar; 19(3):328-331. PubMed ID: 32550694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study.
    Guerra I; Pérez-Jeldres T; Iborra M; Algaba A; Monfort D; Calvet X; Chaparro M; Mañosa M; Hinojosa E; Minguez M; Ortiz de Zarate J; Márquez L; Prieto V; García-Sánchez V; Guardiola J; Rodriguez GE; Martín-Arranz MD; García-Tercero I; Sicilia B; Masedo Á; Lorente R; Rivero M; Fernández-Salazar L; Gutiérrez A; Van Domselaar M; López-SanRomán A; Ber Y; García-Sepulcre M; Ramos L; Bermejo F; Gisbert JP;
    Inflamm Bowel Dis; 2016 Apr; 22(4):894-901. PubMed ID: 26933750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis.
    Xie W; Xiao S; Huang H; Zhang Z
    Front Immunol; 2022; 13():847160. PubMed ID: 35300336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pattern and Severity of Psoriasiform Eruptions in Patients with Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders Treated with TNF-alpha Inhibitors.
    Darrigade AS; Milpied B; Truchetet ME; Schaeverbeke T; Laharie D; Zerbib F; Beylot-Barry M; Jouary T; Taïeb A; Ezzedine K; Seneschal J
    Acta Derm Venereol; 2017 Jun; 97(6):731-734. PubMed ID: 28218339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis.
    Vasconcellos JB; Pereira DD; Vargas TJ; Levy RA; Pinheiro GD; Cursi ÍB
    An Bras Dermatol; 2016; 91(5 suppl 1):137-139. PubMed ID: 28300922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
    Protic M; Schoepfer A; Yawalkar N; Vavricka S; Seibold F
    Scand J Gastroenterol; 2016 Dec; 51(12):1482-1488. PubMed ID: 27534974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Paradoxical psoriasis induced by anti-TNF - a clinical challenge].
    Nidegger A; Mylonas A; Conrad C
    Rev Med Suisse; 2019 Mar; 15(644):668-671. PubMed ID: 30916904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dermatological Manifestations in Pediatric Patients with Inflammatory Bowel Diseases on Anti-TNF Therapy.
    Sridhar S; Maltz RM; Boyle B; Kim SC
    Inflamm Bowel Dis; 2018 Aug; 24(9):2086-2092. PubMed ID: 29718343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
    Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paradoxical Autoinflammatory Skin Reaction to Tumor Necrosis Factor Alpha Blockers Manifesting as Amicrobial Pustulosis of the Folds in Patients With Inflammatory Bowel Diseases.
    Marzano AV; Tavecchio S; Berti E; Gelmetti C; Cugno M
    Medicine (Baltimore); 2015 Nov; 94(45):e1818. PubMed ID: 26559252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
    Fiorino G; Allez M; Malesci A; Danese S
    Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-tumour necrosis factor-induced skin rashes in inflammatory bowel disease: a systematic review and evidence-based management algorithm.
    Au M; Heddle G; Young E; Ryan E; Graf S; Tee D; Philpott H
    Intern Med J; 2023 Oct; 53(10):1854-1865. PubMed ID: 35760771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psoriasis induced by infliximab in a patient suffering from Crohn's disease.
    Manni E; Barachini P
    Int J Immunopathol Pharmacol; 2009; 22(3):841-4. PubMed ID: 19822070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
    Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
    Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents.
    Guerra I; Gisbert JP
    Expert Rev Gastroenterol Hepatol; 2013 Jan; 7(1):41-8. PubMed ID: 23265148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful management of infliximab-induced generalized pustular psoriasis without therapy discontinuation in a patient with psoriatic arthritis.
    Zheng J; Gao Y; Ding Y
    Dermatol Ther; 2019 Nov; 32(6):e13132. PubMed ID: 31631466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy.
    Nigam GB; Bhandare AP; Antoniou GA; Limdi JK
    Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):346-357. PubMed ID: 32889976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.